Centessa: Shift In Focus With ORX750 Development Continues To Pay Off
Portfolio Pulse from
Centessa Pharmaceuticals has shifted its focus from SerpinPC to ORX750, resulting in $200 million in net savings. Positive results from a phase 1 study of ORX750 for sleep-deprived volunteers were reported, with further phase 2a results expected in 2025.
December 26, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Centessa Pharmaceuticals has discontinued its SerpinPC program, saving $200 million, and is focusing on ORX750, which showed positive phase 1 results. Phase 2a results are anticipated in 2025.
The decision to shelve SerpinPC and focus on ORX750 has resulted in significant cost savings and positive trial results, which are likely to boost investor confidence and positively impact Centessa's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100